|
|
|||||||||
(Pediatrics in Review. 2008;29:140-142.)
© 2008 American Academy of Pediatrics
In Brief |
| The first 300 words of the full text of this article appear below. |
Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infections in Children and Adolescents. Pediatric Tuberculosis Collaborative Group.
Pediatrics. 2004;114
:1175
–1201
Tuberculosis (TB) is a worldwide scourge, documented in antiquity and reinventing itself with drug resistance and a predilection for the immunodeficient. However, this disease is not confined to the poor and disenfranchised in this global village, and it is no respecter of national borders, being just a plane ride away. The World Health Organization estimates that 2 billion people live with TB, most with latent disease. Some 9 million new cases occur each year, and 5,000 deaths are attributed to TB every day. The United States (US) is spared this high burden of disease. In 2004, an estimated 9.6 to 14.9 million individuals were infected with latent TB, and in 2005, 14,097 adult cases (4.8/100,000 persons) of active disease were reported, an all-time low for the US. In 2005, there also were 863 cases of active TB in children, with 480 of those in children younger than 5 years of age and 383 in those between 5 and 15 years of age, for a rate of 1.4/100,000 children.
The genus Mycobacterium contains M tuberculosis and M bovis, the two most common organisms that cause TB, and the atypical organisms of M scrofulaceum, M kansasii, M marinum, M fortuitum, M chelonei, and M avium-intracellulare complex
Marguerite M. Mayers, MD
Children's Hospital at Montefiore
Bronx, NY
Henry M. Adam, MD, Editor, In Brief
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | CME | ARCHIVE | SEARCH | TABLE OF CONTENTS |